Cardamonin exerts anti-gastric cancer activity via inhibiting LncRNA-PVT1-STAT3 axis

Area of Science:

• Oncology
• Epigenetics
• Natural Products Chemistry

Background:

• Gastric cancer is a leading cause of cancer death globally, with regional variations in clinicopathologic features.
• Epigenetic alterations are crucial in the development of gastric cancer.
• Understanding these mechanisms is key to developing effective treatments.

Purpose of the Study:

• To evaluate cardamonin, a natural chalcone, as a potential therapeutic agent against gastric cancer.
• To investigate the molecular mechanisms underlying cardamonin's anti-cancer effects.
• To explore the role of the LncRNA-PVT1-STAT3 axis in cardamonin's action.

Main Methods:

• Pre-clinical evaluation of cardamonin in gastric cancer models.
• Assessment of cardamonin's effects on cell proliferation, migration, and apoptosis.
• Analysis of gene and protein expression related to apoptosis and migration.
• Investigation of cardamonin's impact on the STAT3 signaling pathway and LncRNA-PVT1.

Main Results:

• Cardamonin demonstrated significant inhibition of gastric cancer cell proliferation and migration.
• Cardamonin induced apoptosis in gastric cancer cells.
• The compound reduced the expression of key apoptosis- and migration-related genes and proteins.
• Cardamonin effectively down-regulated phosphorylated STAT3 (p-STAT3) by inhibiting LncRNA-PVT1 expression, thereby suppressing STAT3 activation.

Conclusions:

• Cardamonin exhibits potent anti-gastric cancer properties in pre-clinical studies.
• The anti-cancer effects are mediated through epigenetic modulation of the LncRNA-PVT1-STAT3 signaling pathway.
• Cardamonin represents a promising natural source for developing novel anti-gastric cancer therapeutics.